# colorectal cancer - glm-5.2

- Benchmark system: E2seq + Agent RAG
- Repeat: 6
- Task type: PROGNOSIS
- Tissue / sample source: colorectal tumor tissue
- Comparison or endpoint: overall survival (OS)
- Answer input cohort: Discovery/Core only
- Selected items: 100
- Input fields: gene name, effect size (log2FC/HR), P value, FDR
- E2seq Agent RAG: enabled
- Conversation memory: disabled
- Thinking mode: disabled
- Held-out validation data in prompt/RAG: no
- Model API: Zhipu AI / glm-5.2
- Message SHA-256: dfb8fe82357dbea353d34030380d74028b528c91505f5793c7261ee9e4376675
- Response HTTP status: 200
- Prompt tokens: 26101
- Completion tokens: 11244
- Reasoning tokens: 0
- Total tokens: 37345
- API requests reported: 2
- Elapsed seconds: 149.335
- RAG status: reused_or_ready
- RAG records/genes reported: 100
- RAG elapsed seconds: 1848.064
- Question handoff seconds: 1861.273
- Final benchmark system: E2seq; file rank 4/5; original repeat 6; model vendor: Zhipu AI

---
# Multidimensional Interpretation of Prognostic Transcriptomic Features in Colorectal Cancer (OS Endpoint)

## Data-Quality Advisory
Before interpreting the biological signals, several technical features of the uploaded dataset must be noted. The cohort contains 100 unique genes derived from 209 input rows, with 53 duplicated genes or probes. Most notably, some genes (e.g., *DCBLD2*, *LOC101928747|RBMX|SNORD61*, *BCL2L14*) exhibit **direction conflicts** across duplicate rows, meaning opposite hazard ratios were recorded for the same gene identifier in the uploaded file. While the ledger's representative rows are used for the primary interpretation, these conflicts reduce the reliability of individual gene-level point estimates for those specific entries. Furthermore, **external statistical validation was not performed**; no independent cohort statistic was supplied. External database records (Reactome, STRING, literature, etc.) are used strictly as contextual annotation, not as replication.

---

## 1. Overall Biological Interpretation

The prognostic landscape defined by these 100 genes in colorectal cancer (CRC) overall survival reveals a tension between two opposing cellular states. On the risk side (HR > 1), the dominant signals converge on **EMT/stromal activation, cytoskeletal remodeling, and invasive front biology**, exemplified by genes such as *ZEB1-AS1*, *TPM4*, *AKT3*, *ABL2*, *NAV3*, and *MAP1B*. These genes collectively suggest that tumors with poor prognosis are enriched for mesenchymal transition and motility programs. Concurrently, a distinct set of risk genes—including *INHBB*, *MSLN*, *NT5E*, *SCARA3*, and *FGF19*—points toward **immune-evasive and tumor-microenvironment (TME) remodeling programs**, where elevated expression of these factors may reflect an immunosuppressive or pro-angiogenic milieu.

On the protective side (HR < 1), the most coherent signal is **loss of intestinal epithelial identity and mitochondrial oxidative metabolism**. The protective association of key colonocyte lineage transcription factors (*CDX2*, *CDX1*, *MYB*) and differentiation markers (*LGALS4*, *SCEL*) is counterintuitive and may reflect either a genuine biological relationship (e.g., these factors being downregulated in aggressive, dedifferentiated tumors where their residual expression marks a less aggressive subtype) or a **confounding effect of tumor cellularity** (see Limitations). Additionally, a cluster of protective genes involved in mitochondrial respiration and metabolism (*NDUFA9*, *CS*, *ATP5B*, *ATP5G1*, *OGDHL*) suggests that preserved oxidative phosphorylation capacity is associated with better OS, consistent with metabolic reprogramming literature in CRC.

---

## 2. Core Biological Programs

### Program 1: Epithelial-Mesenchymal Transition (EMT) and Stromal Activation
- **Direction/Prognostic association:** Risk-associated (HR > 1)
- **Major supporting genes:** *ZEB1-AS1* (HR=1.372, FDR=0.009), *TPM4* (HR=1.364, FDR=0.009), *AKT3* (HR=1.318, FDR=0.039), *ABL2* (HR=1.301, FDR=0.028), *ITGBL1* (HR=1.299, FDR=0.031), *SCEL* (HR=1.254, FDR=0.039), *BICD1* (HR=1.293, FDR=0.068)
- **Standardized pathway:** Hallmark_EMT; Reactome "Signaling by FGFR" (via *FGF19*); KEGG "Focal adhesion" (via *ITGBL1*, *ABL2*, *AKT3*)
- **Explanation:** *ZEB1-AS1* is a well-characterized lncRNA that epigenetically activates the EMT-inducing transcription factor ZEB1. Its co-occurrence with cytoskeletal genes (*TPM4*, *BICD1*), a signaling kinase driving mesenchymal migration (*AKT3*), and an integrin-binding protein (*ITGBL1*) forms a coherent EMT/stromal program. Higher expression of these genes reflecting an activated mesenchymal state is biologically concordant with worse OS.
- **Evidence strength & limitations:** Direct input/uploaded evidence is strong (multiple genes at FDR < 0.05). External/independent literature and pathway annotations support the EMT characterization of these genes. However, EMT signatures are notoriously confounded by tumor stromal content (fibroblast contamination), and the current dataset cannot distinguish tumor-intrinsic EMT from stromal cell admixture.

### Program 2: Immune Evasion and Tumor Microenvironment Remodeling
- **Direction/Prognostic association:** Risk-associated (HR > 1) for *MSLN*, *NT5E*; Protective (HR < 1) for *LGALS9*, *CCL15*, *TAPBPL*
- **Major supporting genes:** *MSLN* (HR=1.313, FDR=0.045), *NT5E* (HR=1.313, FDR=0.039), *SCARA3* (HR=1.377, FDR=0.002), *INHBB* (HR=1.433, FDR=0.001), *LGALS9* (HR=0.753, FDR=0.042), *CCL15-CCL14|CCL15* (HR=0.753, FDR=0.036), *TAPBPL* (HR=0.711, FDR=0.019)
- **Standardized pathway:** GO: Regulation of T cell migration (GO:2000404); Reactome "Antigen processing: Loading onto MHC class I" (via *TAPBPL*)
- **Explanation:** This program is bifaceted. On the risk side, *NT5E* (encoding CD73) generates immunosuppressive adenosine in the TME, and *MSLN* (mesothelin) is a tumor-associated antigen linked to immune evasion. *INHBB* (inhibin subunit beta B) is the top-ranked risk gene (HR=1.433) and has recently been linked to poor prognosis in CRC (Europe PMC:41992239). On the protective side, *LGALS9* (galectin-9) is a ligand for the immune checkpoint receptor TIM-3; its protective association may reflect a complex immune-modulatory role that is context-dependent in CRC. *TAPBPL*, involved in MHC class I antigen peptide loading, being protective aligns with the importance of intact antigen presentation for anti-tumor immunity. *CCL15*, a chemokine that can recruit immunosuppressive myeloid cells, being protective is directionally unexpected and may reflect specific CRC stage-dependent biology.
- **Evidence strength & limitations:** The GO term "regulation of T cell migration" was directly retrieved in the question-time batch, supporting the immunological coherence. The literature supports *NT5E*/CD73 as a cancer prognostic and immunotherapy target (PMID: 36480312) and *INHBB* as a poor prognostic factor in CRC (Europe PMC: 41992239). The major limitation is that immune signals in bulk tumor transcriptomics are heavily confounded by immune cell infiltration fraction, which cannot be deconvoluted from the current data.

### Program 3: Intestinal Epithelial Differentiation and Lineage Identity
- **Direction/Prognostic association:** Protective-associated (HR < 1)
- **Major supporting genes:** *CDX2* (HR=0.748, FDR=0.036), *MYB* (HR=0.771, FDR=0.019), *CDX1* (HR=0.781, FDR=0.057), *LGALS4* (HR=0.771, FDR=0.051)
- **Standardized pathway:** GO: Cell differentiation; Reactome "Developmental Biology"
- **Explanation:** *CDX2* and *CDX1* are master transcription factors for intestinal epithelial identity, and *MYB* is critical for colonocyte proliferation and differentiation. *LGALS4* (galectin-4) is a colonocyte differentiation marker. Their collective protective association suggests that tumors retaining features of differentiated colonic epithelium have a less aggressive clinical course. Literature evidence specifically supports *CDX2* as a tumor suppressor in CRC via Wnt/β-catenin suppression (PMID: 30631044).
- **Evidence strength & limitations:** The convergence of three independent lineage-defining transcription factors supports this program strongly. However, their protective signal may partly reflect **tumor purity**: well-differentiated tumors with higher epithelial cell content would naturally express higher levels of these markers and tend to have better prognosis, making it difficult to separate causal biology from compositional effects.

### Program 4: Mitochondrial Oxidative Metabolism
- **Direction/Prognostic association:** Protective-associated (HR < 1)
- **Major supporting genes:** *NDUFA9* (HR=0.689, FDR=0.009), *CS* (HR=0.755, FDR=0.039), *ATP5B* (HR=0.748, FDR=0.059), *ATP5G1* (HR=0.747, FDR=0.052), *ATP23* (HR=0.689, FDR=0.007), *OGDHL* (HR=0.686, FDR=0.074)
- **Standardized pathway:** KEGG "Citrate cycle (TCA cycle)"; Reactome "Respiratory electron transport, ATP synthesis"
- **Explanation:** *NDUFA9* (Complex I subunit), *CS* (citrate synthase, rate-limiting TCA enzyme), *ATP5B/ATP5G1* (ATP synthase subunits), and *OGDHL* (oxoglutarate dehydrogenase) are all core mitochondrial oxidative phosphorylation components. Their uniform protective directionality suggests that preserved mitochondrial function is associated with better clinical outcomes in CRC, consistent with the concept that metabolic collapse or a shift toward glycolytic dependency marks aggressive tumor behavior.
- **Evidence strength & limitations:** This is one of the most internally consistent programs in the dataset, with six genes showing concordant protective directions. STRING network evidence connects *CS* with *ACSS2* and *ILVBL* through metabolic enzyme networks. The primary limitation is that mitochondrial gene expression may also reflect overall cellular metabolic activity or proliferation rate rather than a specific causal OXPHOS program.

### Program 5: Tumor Angiogenesis and Hypoxia-Related Signaling
- **Direction/Prognostic association:** Risk-associated (HR > 1)
- **Major supporting genes:** *NPR3* (HR=1.350, FDR=0.016), *FGF19* (HR=1.291, FDR=0.051), *GADD45B* (HR=1.324, FDR=0.063), *CYP1B1* (HR=1.285, FDR=0.063)
- **Standardized pathway:** Reactome "Signaling by FGFR"; GO: Response to hypoxia
- **Explanation:** *NPR3* (natriuretic peptide receptor C) is involved in vascular signaling, and *FGF19* is an endocrine FGF with established roles in CRC progression and angiogenesis. *CYP1B1* is a hypoxia-inducible cytochrome P450, and *GADD45B* is a stress-response gene. Together, these genes suggest that vascular remodeling and stress-response signaling are associated with adverse outcomes.
- **Evidence strength & limitations:** This program is less robust than the others because it relies partly on genes at FDR > 0.05, and the biological connection among these genes is more putative. It should be treated as exploratory.

---

## 3. Key Genes and Interaction Modules

### 1. INHBB
- **Statistical association:** Risk-associated, HR=1.433, P=2.0e-08, FDR=0.001 (strongest signal in dataset)
- **Role in core programs:** Immune/TME remodeling; TGF-β superfamily signaling
- **Gene-gene relationships:** Pathway co-membership with other TGF-β/BMP family members; no direct physical interaction evidence with other selected genes from STRING.
- **Evidence note:** Direct input/uploaded evidence (strongest P-value). External/independent literature (Europe PMC: 41992239) reports high *INHBB* expression is associated with poor prognosis in CRC and drives malignant phenotypes, which is genuinely independent literature support for the direction of the uploaded statistic.

### 2. CDX2
- **Statistical association:** Protective-associated, HR=0.748, P=3.0e-05, FDR=0.036
- **Role in core programs:** Intestinal epithelial differentiation and lineage identity
- **Gene-gene relationships:** Regulatory interaction (TRRUST database): *CDX2* is a transcription factor that regulates downstream intestinal genes. No direct physical interaction with other selected genes is evidenced.
- **Evidence note:** Direct input/uploaded evidence plus literature support (PMID: 30631044) showing *CDX2* inhibits CRC proliferation via Wnt/β-catenin suppression.

### 3. NT5E (CD73)
- **Statistical association:** Risk-associated, HR=1.313, P=4.3e-05, FDR=0.039
- **Role in core programs:** Immune evasion (adenosine-mediated immunosuppression)
- **Gene-gene relationships:** Pathway co-membership with purinergic signaling; no direct physical interaction with other selected genes.
- **Evidence note:** Literature (PMID: 36480312) supports *NT5E*/CD73 as a cancer prognostic biomarker and immunotherapy target across multiple cancer types.

### 4. NDUFA9 / ATP23 (Mitochondrial Module)
- **Statistical association:** Both protective-associated; *NDUFA9* HR=0.689 (FDR=0.009), *ATP23* HR=0.689 (FDR=0.007)
- **Role in core programs:** Mitochondrial oxidative metabolism
- **Gene-gene relationships:** Pathway co-membership in oxidative phosphorylation. *ATP23* literature (PMID: 17135288) describes it as a processing peptidase and chaperone for the F1Fo-ATP synthase, functionally linking it to the same complex as *ATP5B* and *ATP5G1*. No direct physical interaction between *NDUFA9* and *ATP23* is recorded in STRING among the selected genes.
- **Evidence note:** The concordance of multiple OXPHOS genes is a direct input/uploaded-level signal.

### 5. ZEB1-AS1
- **Statistical association:** Risk-associated, HR=1.372, P=9.8e-07, FDR=0.009
- **Role in core programs:** EMT and stromal activation
- **Gene-gene relationships:** Regulatory interaction (indirect): *ZEB1-AS1* is a lncRNA that epigenetically regulates *ZEB1* (not in the selected gene list), which in turn transcriptionally represses epithelial markers. This is a regulatory relationship, not a direct physical interaction.
- **Evidence note:** Direct input/uploaded evidence with strong FDR. External/independent literature extensively documents the *ZEB1-AS1*/ZEB1 axis in CRC EMT.

### 6. AKT3
- **Statistical association:** Risk-associated, HR=1.318, P=3.6e-05, FDR=0.039
- **Role in core programs:** EMT/stromal activation; PI3K-Akt signaling
- **Gene-gene relationships:** Pathway co-membership with *ABL2* in focal adhesion and cytoskeletal remodeling signaling. STRING edges may exist with other signaling partners outside the selected gene set, but no direct physical interaction among selected genes is confirmed.
- **Evidence note:** *AKT3* had 7 duplicate rows in the ledger, and direction conflicts were noted in the broader dataset, warranting caution in its individual interpretation.

### 7. SCARA3
- **Statistical association:** Risk-associated, HR=1.377, P=8.9e-08, FDR=0.002
- **Role in core programs:** Potentially involved in TME remodeling; scavenger receptor activity
- **Gene-gene relationships:** Insufficient evidence for specific gene-gene interactions among selected genes.
- **Evidence note:** One of the top-ranked genes by P-value. *SCARA3* is less well-characterized in CRC; its role in oxidative stress response and scavenging may link to the metabolic/oxidative stress program.

### 8. LGALS9
- **Statistical association:** Protective-associated, HR=0.753, P=5.3e-05, FDR=0.042
- **Role in core programs:** Immune modulation (TIM-3 ligand)
- **Gene-gene relationships:** No direct physical interactions with other selected genes evidenced.
- **Evidence note:** The protective direction of *LGALS9* is notable because, as a TIM-3 ligand, it is often associated with T-cell exhaustion in other contexts. Its protective association in CRC OS may reflect a distinct role in regulating tumor-intrinsic apoptosis or a different immune context.

### 9. MSLN (Mesothelin)
- **Statistical association:** Risk-associated, HR=1.313, P=6.1e-05, FDR=0.045
- **Role in core programs:** Immune evasion; tumor-associated antigen
- **Gene-gene relationships:** No direct physical interactions among selected genes.
- **Evidence note:** Literature (Europe PMC: 42363170) describes next-generation mesothelin-targeted CAR-T cells for CRC organoids, providing therapeutic relevance context, though this does not validate the prognostic association.

### 10. MYB
- **Statistical association:** Protective-associated, HR=0.771, P=5.3e-06, FDR=0.019
- **Role in core programs:** Intestinal epithelial differentiation and lineage identity
- **Gene-gene relationships:** STRING records direct physical interactions with *CREBBP*, *EP300*, and *GATA2* (none of which are in the selected gene list), supporting its role as a transcriptional regulator. No direct physical interaction with other selected genes.
- **Evidence note:** Direct input/uploaded evidence; *MYB* is an established CRC tumor suppressor-like factor whose loss is associated with tumor progression.

---

## 4. Validation Priorities

### Priority 1: INHBB as a prognostic biomarker and mechanistic driver in CRC
- **Classification:** Biomarker / Mechanistic hypothesis
- **Why:** *INHBB* is the top-ranked risk gene (HR=1.433, FDR=0.001) with directly concordant external/independent literature reporting poor prognosis in CRC (Europe PMC: 41992239).
- **Current dataset evidence:** Strong direct survival association; largest effect size among FDR-significant genes.
- **External evidence:** A published study specifically links high *INHBB* expression to poor prognosis and malignant phenotypes in CRC.
- **Next step:** Validate in an independent CRC cohort with OS endpoint (e.g., TCGA-COADREAD); perform functional studies (knockdown/overexpression) to test whether *INHBB* drives invasion or proliferation.
- **Conclusion status:** **Supported hypothesis** (biomarker); **Exploratory hypothesis** (mechanistic driver).

### Priority 2: Immune evasion axis (NT5E/CD73–MSLN) as a therapeutic target candidate
- **Classification:** Therapeutic target / Interaction hypothesis
- **Why:** Both *NT5E* and *MSLN* are risk-associated genes with established immunotherapeutic relevance. Anti-CD73 antibodies and mesothelin-targeted CAR-T cells are in clinical development.
- **Current dataset evidence:** Both genes show FDR-significant risk associations (*NT5E* FDR=0.039, *MSLN* FDR=0.045).
- **External evidence:** *NT5E*/CD73 is supported as a pan-cancer prognostic and immunotherapy biomarker (PMID: 36480312). MSLN-targeted CAR-T cells have been tested in CRC organoids (Europe PMC: 42363170).
- **Next step:** Correlate *NT5E* and *MSLN* expression with immune infiltration scores and response to immune checkpoint inhibitors in CRC cohorts. The existence of drugs targeting these pathways does not by itself confirm therapeutic efficacy in this disease context.
- **Conclusion status:** **Exploratory hypothesis** for therapeutic targeting in CRC specifically.

### Priority 3: Tumor purity and epithelial composition as confounders of the protective differentiation signal
- **Classification:** Confounding or composition check
- **Why:** The protective associations of *CDX2*, *CDX1*, *MYB*, and *LGALS4* could ref

E2seq statistical audit: selected=100, ledger=100, RAG records=100, numeric claims checked=66, external claims checked=0, external mismatches=0, status=needs review.

Answer model API: Zhipu AI / glm-5.2

Source coverage (gene sources = selected items with records / selected RAG items; literature sources = articles / queries)
Online APIs: alliance 86/100 selected items (records returned); cbioportal 78/100 selected items (records returned); chembl 14/100 selected items (partially returned; some queries failed); civic 7/100 selected items (records returned); clinicaltrials 32/100 selected items (records returned); clinvar 83/100 selected items (records returned); ensembl 41/100 selected items (partially returned; some queries failed); europepmc 866 articles / initial full-cohort RAG 100 queries + 4 current-round queries; gtex 81/100 selected items (records returned); gwas 100/100 selected items (records returned); hpa 75/100 selected items (records returned); humanbase 78/100 selected items (records returned); intact 78/100 selected items (records returned); mygene 86/100 selected items (records returned); omnipath 32/100 selected items (records returned); opentargets 40/100 selected items (partially returned; some queries failed); pubmed 699 articles / initial full-cohort RAG 100 queries + 3 current-round queries; quickgo 79/100 selected items (records returned); reactome 100/100 selected items (records returned); uniprot 80/100 selected items (records returned)
Local databases: gutmgene 0/100 selected items (reachable but no records for this batch); hmdb 25/100 selected items (records returned); string 73/100 selected items (records returned); trrust 14/100 selected items (records returned)
